| Literature DB >> 27776508 |
Tahira Younis1, Muhammad Rashid Khan2, Moniba Sajid1.
Abstract
BACKGROUND: Leaves and root bark of Fraxinus xanthoxyloides Wall. (Oleaceae) are used locally for the treatment of jaundice, malaria and pneumonia. Decoction of stem, twigs and bark is used in pain, internal injuries, rheumatism and in bone fracture. In this investigation we have evaluated the methanol extract of leaves for its hepatoprotective potential against CCl4 induced hepatic injuries in rat.Entities:
Keywords: Antioxidant; CCl4; Fraxinus xanthoxyloides; Lipid peroxidation; Liver; Phenolics
Mesh:
Substances:
Year: 2016 PMID: 27776508 PMCID: PMC5078913 DOI: 10.1186/s12906-016-1398-0
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1HPLC-DAD profile of the crude methanol extract of F. xanthoxyloides (FXM)
Effect of FXM on biochemical parameters of serum in rat
| Treatment | AST (U/l) | ALT (U/l) | Bilirubin (mg/dl) | Albumin (mg/dl) | Globulin (mg/dl) |
|---|---|---|---|---|---|
| Control | 86.66 ± 5.35d | 32.66 ± 4.17 d | 0.165 ± 0.024c | 4.45 ± 0.27a | 1.55 ± 0.18c |
| DMSO + Olive oil | 89.50 ± 6.05 d | 33.16 ± 3.65 d | 0.160 ± 0.025c | 4.60 ± 0.17a | 1.52 ± 0.18bc |
| CCl4 | 319.83 ± 20.22†a | 204.67 ± 20.91†a | 0.663 ± 0.132†a | 2.33 ± 0.31†b | 2.27 ± 0.10†a |
| CCl4 + silymarin (100 mg/kg) | 122.00 ± 21.07≠c | 63.50 ± 5.28†c | 0.256 ± 0.043*bc | 3.93 ± 0.21a | 1.81 ± 0.26bc |
| CCl4 + FXM (200 mg/kg) | 212.67 ± 29.04†b | 105.50 ± 6.53†b | 0.325 ± 0.030†b | 4.00 ± 0.50a | 2.13 ± 0.09†ab |
| CCl4 + FXM (400 mg/kg) | 116.83 ± 12.25*cd | 61.33 ± 6.21†c | 0.161 ± 0.030c | 4.23 ± 0.47a | 2.09 ± 0.23†ab |
| FXM (200 mg/kg) | 84.83 ± 5.07 d | 36.66 ± 3.66 d | 0.156 ± 0.021c | 4.35 ± 0.18a | 1.51 ± 0.14c |
| FXM (400 mg/kg) | 86.66 ± 4.88 d | 33.16 ± 3.06 d | 0.161 ± 0.023c | 4.43 ± 0.32a | 1.60 ± 0.14c |
FXM F. xanthoxyloides methanol extract. Data values shown represent mean ± SD (n = 6). One way analysis of variance was followed by Dunnet comparison of various treatments with control at: *, P < 0.05; #, P < 0.01; ǂ, P < 0.001. Multiple comparisons among treatments were determined by Tukeys’ HSD test. Superscript alphabets indicate significance among treatments (P < 0.01) on not sharing common letter
Effect of FXM on antioxidant enzymes of liver in rat
| Treatment | CAT (U/min) | POD (U/min) | SOD (U/mg protein) | GST (mM/min/mg protein) | GSR (mM//min/mg protein) |
|---|---|---|---|---|---|
| Control | 3.88 ± 0.53ab | 9.55 ± 0.99ab | 3.00 ± 0.31a | 160.81 ± 8.53a | 224.62 ± 9.02a |
| DMSO + Olive oil | 4.19 ± 0.27a | 10.65 ± 1.44ab | 3.07 ± 0.27a | 158.56 ± 11.67a | 220.11 ± 8.01a |
| CCl4 | 2.33 ± 0.18†c | 5.31 ± 0.63†c | 1.30 ± 0.23†c | 100.11 ± 4.99†c | 130.52 ± 9.77†d |
| CCl4 + silymarin (100 mg/kg) | 3.88 ± 0.28ab | 9.31 ± 0.67ab | 2.93 ± 0.23ab | 151.02 ± 9.49ab | 180.88 ± 9.17†c |
| CCl4 + FXM (200 mg/kg) | 2.64 ± 0.15†c | 7.45 ± 0.39†b | 1.58 ± 0.11†c | 133.85 ± 8.34†b | 184.83 ± 8.90†c |
| CCl4 + FXM (400 mg/kg) | 3.37 ± 0.24*b | 9.01 ± 0.55ab | 2.46 ± 0.19≠b | 150.70 ± 8.98ab | 198.03 ± 10.64†bc |
| FXM (200 mg/kg) | 3.79 ± 0.23ab | 9.44 ± 0.87ab | 2.99 ± 0.18a | 159.57 ± 9.57a | 221.17 ± 7.15a |
| FXM (400 mg/kg) | 3.91 ± 0.45ab | 9.59 ± 0.75ab | 2.94 ± 0.20ab | 159.66 ± 9.63a | 216.03 ± 8.42ab |
FXM F. xanthoxyloides methanol extract. Data values shown represent mean ± SD (n = 6). One way analysis of variance was followed by Dunnet comparison of various treatments with control at: *, P < 0.05; #, P < 0.01; ǂ, P < 0.001. Multiple comparisons among treatments were determined by Tukeys’ HSD test. Superscript alphabets indicate significance among treatments (P < 0.01) on not sharing common letter
Effect of FXM on biochemical parameters of liver in rat
| Treatment | Protein (μg/mg tissue) | GSH (μmole/g tissue) | TBARS (nmole/min/mg tissue) | H2O2 (nmole/min/mg tissue) | DNA injury (%) |
|---|---|---|---|---|---|
| Control | 2.98 ± 0.13a | 21.05 ± 2.18abc | 2.96 ± 0.28d | 2.49 ± 0.09c | 2.51 ± 0.15d |
| DMSO + Olive oil | 2.98 ± 0.09a | 21.35 ± 2.16ab | 3.24 ± 0.36d | 2.60 ± 0.19bc | 2.58 ± 0.15d |
| CCl4 | 1.05 ± 0.14†c | 11.38 ± 0.93†e | 6.19 ± 0.65†a | 3.99 ± 0.33†a | 6.22 ± 0.63†a |
| CCl4 + silymarin (100 mg/kg) | 2.81 ± 0.10a | 17.87 ± 1.01≠bcd | 4.20 ± 0.27†bc | 2.93 ± 0.20*bc | 2.94 ± 0.21cd |
| CCl4 + FXM (200 mg/kg) | 1.87 ± 0.13†b | 14.62 ± 1.56d†e | 4.65 ± 0.47†b | 3.04 ± 0.25≠b | 4.50 ± 0.34†b |
| CCl4 + FXM (400 mg/kg) | 2.91 ± 0.11a | 17.73 ± 1.00≠cd | 3.80 ± 0.34≠cd | 2.74 ± 0.35bc | 3.38 ± 0.23†c |
| FXM (200 mg/kg) | 2.90 ± 0.13a | 21.74 ± 1.82a | 2.95 ± 0.19d | 2.51 ± 0.21c | 2.55 ± 0.09d |
| FXM (400 mg/kg) | 2.89 ± 0.11a | 22.35 ± 1.65a | 3.13 ± 0.33d | 2.49 ± 0.18c | 2.49 ± 0.16d |
FXM F. xanthoxyloides methanol extract. Data values shown represent mean ± SD (n = 6). One way analysis of variance was followed by Dunnet comparison of various treatments with control at: *, P < 0.05; #, P < 0.01; ǂ, P < 0.001. Multiple comparisons among treatments were determined by Tukeys’ HSD test. Superscript alphabets indicate significance among treatments (P < 0.01) on not sharing common letter
Effect of FXM on comet parameters of liver cells in rat
| Treatment | Comet length (μm) | Head length (μm) | Tail length (μm) | DNA head (%) | DNA tail (%) | Tail moment (μm) |
|---|---|---|---|---|---|---|
| Control | 33.26 ± 1.17d | 26.55 ± 1.14c | 6.71 ± 1.85d | 96.81 ± 0.94a | 3.18 ± 0.94d | 0.51 ± 0.02c |
| DMSO + Olive oil | 33.16 ± 1.03d | 26.27 ± 0.36c | 6.88 ± 1.29d | 96.89 ± 1.00a | 3.10 ± 1.00d | 0.52 ± 0.01c |
| CCl4 | 65.21 ± 1.74ǂa | 42.01 ± 2.02ǂa | 23.20 ± 2.56ǂa | 70.00 ± 1.54ǂd | 29.99 ± 1.54ǂa | 1.80 ± 0.10ǂa |
| CCl4 + silymarin (100 mg/kg) | 40.79 ± 1.67ǂc | 28.71 ± 1.01*c | 12.07 ± 1.56ǂbc | 89.81 ± 1.13ǂb | 10.18 ± 1.13ǂc | 0.60 ± 0.03≠bc |
| CCl4 + FXM (200 mg/kg) | 49.25 ± 2.32ǂb | 33.29 ± 1.19ǂb | 15.96 ± 3.25ǂb | 85.86 ± 1.68ǂc | 14.14 ± 1.68ǂb | 0.68 ± 0.02ǂb |
| CCl4 + FXM (400 mg/kg) | 40.98 ± 1.68ǂc | 26.86 ± 1.08c | 14.11 ± 1.56ǂb | 90.65 ± 1.32ǂb | 9.35 ± 1.32ǂc | 0.60 ± 0.02≠bc |
| FXM (200 mg/kg) | 33.93 ± 1.60d | 26.22 ± 0.99c | 7.71 ± 2.44cd | 94.74 ± 2.23a | 5.25 ± 2.23d | 0.53 ± 0.01c |
| FXM (400 mg/kg) | 34.32 ± 1.33d | 26.43 ± 1.41c | 7.88 ± 1.60cd | 95.37 ± 1.03a | 4.62 ± 1.03d | 0.53 ± 0.01c |
FXM F. xanthoxyloides methanol extract. Data values shown represent mean ± SD (n = 6). One way analysis of variance was followed by Dunnet comparison of various treatments with control at: *, P < 0.05; #, P < 0.01; ǂ, P < 0.001. Multiple comparisons among treatments were determined by Tukeys’ HSD test. Superscript alphabets indicate significance among treatments (P < 0.01) on not sharing common letter
Fig. 2Comet studies of hepatic tissues. Ethidium bromide stain; 40× (a) Untreated control (b) vehicle treated (DMSO + olive oil) (c) CCl4 treated (d) CCl4 + silymarin (100 mg/kg) treated (e) CCl4 + FXM (200 mg/kg) treated (f) CCl4 + FXM (400 mg/kg) treated (g) FXM (200 mg/kg) treated (h) FXM (400 mg/kg) treated rats. FXM; F. xanthoxyloides leaves methanol extract
Fig. 3Histopathological studies of liver. Hematoxylin and eosin stain; 40× (a) Untreated control showing normal histoarchitecture of the hepatic tissues (b) vehicle treated (DMSO + olive oil) showing normal histoarchitecture of the hepatic tissues (c) CCl4 treated showing macrosteatosis (d) CCl4 + silymarin (100 mg/kg) treated showing almost normal histoarchitecture (e) CCl4 + FXM (200 mg/kg) treated showing microsteatosis (f) CCl4 + FXM (400 mg/kg) treated showing mild microsteatosis (g) FXM (200 mg/kg) treated showing normal histoarchitecture of the hepatic tissues (h) FXM (400 mg/kg) treated showing normal histoarchitecture of the hepatic tissues of rat. FXM; F. xanthoxyloides leaves methanol extract